User Tools
health:monoamines
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision | |||
|
health:monoamines [2019/07/08 16:47] marcos |
health:monoamines [2020/04/27 01:48] (current) marcos |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | Before taking any pharmaceutical, [[health:drug-allergy-testing |read this first]]. | ||
| - | ==== Monoamine Neurotransmitters and Mental Health ==== | + | ~~META: |
| + | title = Monoamine Neurotransmitters and Mental Health | ||
| + | ~~ | ||
| - | [[https://en.wikipedia.org/wiki/Monoamine_neurotransmitter |Monoamine neurotranmitters]] include serotonin, dopamine, epinephrine (adrenaline), norepinephrine (noradrenaline), histamine, and a host of other [[https://en.wikipedia.org/wiki/Trace_amine |trace aminos]]. | + | // Before taking any pharmaceutical, [[health:drug-allergy-testing |read this first]]. // |
| + | |||
| + | ====== Monoamines ====== | ||
| + | |||
| + | ===== Monoamine Neurotransmitters and Mental Health ===== | ||
| + | |||
| + | [[https://en.wikipedia.org/wiki/Monoamine_neurotransmitter |Monoamine neurotranmitters]] include serotonin, dopamine, epinephrine (adrenaline), norepinephrine (noradrenaline), histamine, and a host of other [[https://en.wikipedia.org/wiki/Trace_amine |trace amines]]. | ||
| I'm finding studies and articles that disagree with the current trend of treatment, [[sociology:self-governance|influenced by capitalism]], for depression and other afflictions of supposed monoamine imbalance. [[https://www.neuropsychotherapist.com/is-the-low-serotonin-theory-of-depression-wrong |See in this article review]], all the reasons why pharmaceuticals for depression don't make sense, and consider that they have side effects worse than the benefit they may derive. (The article review is based on the 2015 study: [[https://www.ncbi.nlm.nih.gov/pubmed/25625874 |Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response]]) | I'm finding studies and articles that disagree with the current trend of treatment, [[sociology:self-governance|influenced by capitalism]], for depression and other afflictions of supposed monoamine imbalance. [[https://www.neuropsychotherapist.com/is-the-low-serotonin-theory-of-depression-wrong |See in this article review]], all the reasons why pharmaceuticals for depression don't make sense, and consider that they have side effects worse than the benefit they may derive. (The article review is based on the 2015 study: [[https://www.ncbi.nlm.nih.gov/pubmed/25625874 |Is serotonin an upper or a downer? The evolution of the serotonergic system and its role in depression and the antidepressant response]]) | ||
| Line 11: | Line 18: | ||
| A 2012 article by Shai Mulnari of Lund University: [[https://www.researchgate.net/publication/230796335_Monoamine_Theories_of_Depression_Historical_Impact_on_Biomedical_Research |Monoamine Theories of Depression: Historical Impact on Biomedical Research]]: " The article argues that the impact of monoamine theories is best explained by the ability of researchers, governmental agencies, and pharmaceutical companies to invoke theories that advance various projects and agendas. " | A 2012 article by Shai Mulnari of Lund University: [[https://www.researchgate.net/publication/230796335_Monoamine_Theories_of_Depression_Historical_Impact_on_Biomedical_Research |Monoamine Theories of Depression: Historical Impact on Biomedical Research]]: " The article argues that the impact of monoamine theories is best explained by the ability of researchers, governmental agencies, and pharmaceutical companies to invoke theories that advance various projects and agendas. " | ||
| - | ==== Treatment Strategy *if* Depression is a Monoamine Deficiency ==== | + | ===== Treatment Strategy *if* Depression is a Monoamine Deficiency ===== |
| Monoamine Transporter Optimization MTO, from the study "[[https://www.ncbi.nlm.nih.gov/pubmed/22615537 |Relative nutritional deficiencies associated with centrally acting monoamines]]": " Humans suffering from chronic centrally acting monoamine-related disease are not suffering from a drug deficiency; they are suffering from a relative nutritional deficiency involving serotonin and dopamine amino acid precursors. Whenever low or inadequate levels of monoamine neurotransmitters exist, a relative nutritional deficiency is present. " | Monoamine Transporter Optimization MTO, from the study "[[https://www.ncbi.nlm.nih.gov/pubmed/22615537 |Relative nutritional deficiencies associated with centrally acting monoamines]]": " Humans suffering from chronic centrally acting monoamine-related disease are not suffering from a drug deficiency; they are suffering from a relative nutritional deficiency involving serotonin and dopamine amino acid precursors. Whenever low or inadequate levels of monoamine neurotransmitters exist, a relative nutritional deficiency is present. " | ||
| Line 40: | Line 47: | ||
| " Kava-kava extract was found to be a reversible inhibitor of MAO-B in intact platelets (IC50 24 microM) and disrupted platelet homogenates (IC50 1.2 microM). Structural differences of kava pyrones resulted in a different potency of MAO-B inhibition. The order of potency was desmethoxyyangonin > (+/-)-methysticin > yangonin > (+/-)-dihydromethysticin > (+/-)- dihydrokavain > (+/-)-kavain. The two most potent kava pyrones, desmethoxyyangonin and (+/-)-methysticin displayed a competetive inhibition pattern with mean Ki 0.28 microM and 1.14 microM respectively. " [[https://www.ncbi.nlm.nih.gov/pubmed/9832350 |1]] | " Kava-kava extract was found to be a reversible inhibitor of MAO-B in intact platelets (IC50 24 microM) and disrupted platelet homogenates (IC50 1.2 microM). Structural differences of kava pyrones resulted in a different potency of MAO-B inhibition. The order of potency was desmethoxyyangonin > (+/-)-methysticin > yangonin > (+/-)-dihydromethysticin > (+/-)- dihydrokavain > (+/-)-kavain. The two most potent kava pyrones, desmethoxyyangonin and (+/-)-methysticin displayed a competetive inhibition pattern with mean Ki 0.28 microM and 1.14 microM respectively. " [[https://www.ncbi.nlm.nih.gov/pubmed/9832350 |1]] | ||
| - | ==== Homeostasis ==== | + | ===== Homeostasis ===== |
| So what metabolic systems drive homeostasis? Are they fully known? Probably not. I've been searching, and I found what seems like a good article, but it is behind a paywall: Brain Monoamines, Homeostasis, and Adaptive Behavior https://onlinelibrary.wiley.com/doi/pdf/10.1002/cphy.cp010413 | So what metabolic systems drive homeostasis? Are they fully known? Probably not. I've been searching, and I found what seems like a good article, but it is behind a paywall: Brain Monoamines, Homeostasis, and Adaptive Behavior https://onlinelibrary.wiley.com/doi/pdf/10.1002/cphy.cp010413 | ||
| Line 86: | Line 93: | ||
| - | ==== Related Research ==== | + | ===== Related Research ===== |
| Time-release 5-htp: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946063. | Time-release 5-htp: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4946063. | ||
health/monoamines.txt · Last modified: 2020/04/27 01:48 by marcos
Page Tools
Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
